Simris Alg AB (publ) (SIMRIS-B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Simris Alg AB (publ) (SIMRIS-B) has a cash flow conversion efficiency ratio of -0.723x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-3.97 Million ≈ $-426.91K USD) by net assets (Skr5.49 Million ≈ $590.38K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Simris Alg AB (publ) (SIMRIS-B) liquidity interval to measure how many days the company can operate on defensive assets alone.
Simris Alg AB (publ) - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Simris Alg AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Simris Alg AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Simris Alg AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VIMAB Group AB
ST:VIMAB
|
3.682x |
|
Cocrystal Pharma Inc
NASDAQ:COCP
|
-0.569x |
|
Crown Lifters Limited
NSE:CROWN
|
0.022x |
|
Skillful Craftsman Education Tech
NASDAQ:EDTK
|
-0.079x |
|
Coast Copper Corp
V:COCO
|
-0.086x |
|
Samil Co.Ltd
KQ:032280
|
0.015x |
|
Capital Engineering Network Public Company Limited
BK:CEN
|
0.024x |
|
Nafpaktos Textile Industry S.A
AT:NAYP
|
0.024x |
Annual Cash Flow Conversion Efficiency for Simris Alg AB (publ) (2014–2025)
The table below shows the annual cash flow conversion efficiency of Simris Alg AB (publ) from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Simris Alg AB (publ) worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr-470.00K ≈ $-50.58K |
Skr-16.05 Million ≈ $-1.73 Million |
34.138x | +1168.91% |
| 2024-12-31 | Skr5.64 Million ≈ $607.06K |
Skr-18.02 Million ≈ $-1.94 Million |
-3.194x | -125.03% |
| 2023-12-31 | Skr25.61 Million ≈ $2.76 Million |
Skr-36.35 Million ≈ $-3.91 Million |
-1.419x | -79.74% |
| 2022-12-31 | Skr23.03 Million ≈ $2.48 Million |
Skr-18.19 Million ≈ $-1.96 Million |
-0.790x | +20.67% |
| 2021-12-31 | Skr18.22 Million ≈ $1.96 Million |
Skr-18.14 Million ≈ $-1.95 Million |
-0.995x | -142.26% |
| 2020-12-31 | Skr47.42 Million ≈ $5.10 Million |
Skr-19.48 Million ≈ $-2.10 Million |
-0.411x | +16.96% |
| 2019-12-31 | Skr35.00 Million ≈ $3.77 Million |
Skr-17.32 Million ≈ $-1.86 Million |
-0.495x | +11.61% |
| 2018-12-31 | Skr39.78 Million ≈ $4.28 Million |
Skr-22.27 Million ≈ $-2.40 Million |
-0.560x | -1.15% |
| 2017-12-31 | Skr42.68 Million ≈ $4.59 Million |
Skr-23.62 Million ≈ $-2.54 Million |
-0.553x | -93.91% |
| 2016-12-31 | Skr65.32 Million ≈ $7.03 Million |
Skr-18.64 Million ≈ $-2.01 Million |
-0.285x | -32.17% |
| 2015-12-31 | Skr38.68 Million ≈ $4.16 Million |
Skr-8.35 Million ≈ $-898.81K |
-0.216x | +75.83% |
| 2014-12-31 | Skr9.78 Million ≈ $1.05 Million |
Skr-8.73 Million ≈ $-939.92K |
-0.893x | -- |
About Simris Alg AB (publ)
Simris Group AB (PUBL), a biotechnology company, develops antibody-drug conjugate (ADC) payloads in Sweden and internationally. The company develops, manufactures, and sells bioactive substances from cultured microalgae and cyanobacteria. It also offers cosmetics and skincare products; biopharmaceuticals; and dietary supplements. The company was incorporated in 2011 and is headquartered in Hammen… Read more